Nanomedicine's shining armor: understanding and leveraging the metal-phenolic networks
Tang Z., Huang Z., Huang Y., Huang M., Liu H., Du J.
Narrative Review, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Nanobiotechnology (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40025537
- PMCID
- PMC11874145
- DOI
- 10.1186/s12951-025-03210-7
- Citations
- 11
Abstract (original English)
Metal-phenolic networks (MPNs), which comprise supramolecular amorphous networks formed by interlinking polyphenols with metal ions, garner escalating interest within the realm of nanomedicine. Presently, a comprehensive synthesis of the cumulative research advancements and utilizations of MPNs in nanomedicine remains absent. Thus, this review endeavors to firstly delineate the characteristic polyphenols, metal ions, and their intricate interaction modalities within MPNs. Subsequently, it elucidates the merits and demerits of diverse synthesis methodologies employed for MPNs, alongside exploring their potential functional attributes. Furthermore, it consolidates the diverse applications of MPNs across various nanomedical domains encompassing tumor therapy, antimicrobial interventions, medical imaging, among others. Moreover, a meticulous exposition of the journey of MPNs from their ingress into the human body to eventual excretion is provided. Lastly, the persistent challenges and promising avenues pertaining to MPNs are delineated. Hence, this review offering a comprehensive exposition on the current advancements of MPNs in nanomedicine, consequently offering indirect insights into their potential clinical implementation.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.